Patent intelligence · US
US 10959938
Combination of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
Combination of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
Patent details — US 10959938
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 30, 2021
- Expiration
- Mar 25, 2041
- Applicant
- QUANTUM GENOMICS
- Claims
- 4
- CPC classes
- A61K, A61K31/185, A61K31/255, A61K31/401
Quick answer
US 10959938 (Combination of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent) is held by QUANTUM GENOMICS. Status: granted. Granted Mar 30, 2021. Expires Mar 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- QUANTUM GENOMICS
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K31/185, A61K31/255, A61K31/401, A61K31/403, A61K31/41
More from QUANTUM GENOMICS
Related pharmaceutical patents in our USPTO index.
-
US 12391720
Salts and polymorphs of cethromycin for the treatment of disease
granted -
US 12377151
Immobilized endoglycosidase fusion protein and use thereof
granted -
US 12370266
Polymer composite nanomaterial encapsulation system
granted -
US 12318457
Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof
granted -
US 12312377
Biconjugatable labels and methods of use
granted -
US 12195454
Compounds for imaging tau proteins that accumulate in the brain
granted -
US 12102694
Radiolabeled compound producing method and producing apparatus, radiolabeled compound and radioisotope producing apparatus
granted -
US 11999748
Exatecan derivatives, linker-payloads, and conjugates and thereof
granted
Frequently asked questions
What is US patent 10959938?
US 10959938 (Combination of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent) is held by QUANTUM GENOMICS. Status: granted. Granted Mar 30, 2021. Expires Mar 25, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10959938?
QUANTUM GENOMICS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.
When does US 10959938 expire?
Our index shows an expiration date of Mar 25, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.